Gleevec

[Joint Statement] Novartis defeated in its appeal trial, a triumphant victory of World patients fighting back Patent Exclusivity - Welcome the ruling of the Supreme Court of India

요약문: 
The protracted Novartis’ appeal from 2006 for a patent to Gleevec (Leukemia medicine), and against Indian Patent law has finally reached a conclusion. On Apr1, Indian Supreme court dismissed Novartis’ appeal.

Joint Statement

 

 

발표일자: 
2013/04/02

Stop the India-EU FTA Negotiations, Decimator of the 'Pharmacy of the World'!

요약문: 
US and EU are threatening lives of people living with disease now. The India-EU FTA is an agreement which risk patients' health none the more than the KORUS FTA. Especially, the India-EU FTA endangers lives of people living with disease all over the world. We urge the Lee Myoung-bak government to abolish KORUS FTA immediately as well as the India government to stop the India-EU FTA negotiation. We also call for the India Supreme Court to dismiss Swiss pharmaceutical company, Novartis' case toward India's progressive patent law.

 

 

<Statement>

발표일자: 
2011/11/27

Novartis's stubborn Gleevec price means death to patients

요약문: 
Only by this kind of public support was Novartis able to recollect all invested capital within eight months of global marketing of Gleevec. But now, Novartis has twenty years of intellectual property rights.
Novartis's stubborn Gleevec price means death to patients

 

(US $1 => about 1,200 won)

 

발표일자: 
2002/08/01

Patents and Profit: Gleevec Price Talks Break Down.

요약문: 
The National Health Insurance System Board held talks on September 6 to try decide the retail price of Gleevec, a cancer drug used for treating leukemia, only to end by delaying the talks even further. One year has passed since the problem of Gleevec first arose.
Patents and Profit: Gleevec Price Talks Break Down.

 

발표일자: 
2002/11/08

Struggle for Access to Glivec

요약문: 
Struggle for Access to Glivec in South Korea Solidarity Needed Now!!!

Struggle for Access to Glivec
in South Korea
Solidarity Needed Now!!!

Table of Content
- The Beginning: Struggle for Rights of Access to Glivec, Extremely High-Priced Drug
- Excluding Chronic Stage CML Patients out of NHI
- Disapproval of Korean National Health Insurance Price and Temporal Suspension of Glivec Supply in the Market
- What is the problem? Priceless Glivec Kills CML Patients
- What is the problem? Are you asking 30 times of production costs, Novartis?
- What is the problem? Glivec, the Product of Public R&D

발표일자: 
2003/09/25

[Letter] Joint Letter of Korean NGOs to the Indian Embassy in Seoul

요약문: 
On behalf of the 27 Korean NGOs, Trade Unions, I am writing to express our concerns regarding the legal proceedings that Norvatis initiated in India in May 2006, challenging the rejection of its patent application for imatinib mesylate (Gleevec/Glivec) as well as questioning the compliance of the Indian Patents Act with the World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights(TRIPS).

Jan 29, 2007

N. Parthasarathi
Ambassador
Indian Embassy in Seoul
37-3, Hannam-Dong Yongsan-ku,
Seoul, South Korea

Re : The Norvatis' legal action in India on the Patent Law

Dear Ambassador N. Parthasarathi

발표일자: 
2007/01/29